Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Debt (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Total Debt for 14 consecutive years, with $60000.0 as the latest value for Q4 2025.

  • Quarterly Total Debt fell 63.64% to $60000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60000.0 through Dec 2025, down 63.64% year-over-year, with the annual reading at $60000.0 for FY2025, 63.64% down from the prior year.
  • Total Debt hit $60000.0 in Q4 2025 for Guided Therapeutics, down from $108000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $1.2 million in Q2 2024 to a low of $32000.0 in Q3 2022.
  • Historically, Total Debt has averaged $360800.0 across 4 years, with a median of $110000.0 in 2021.
  • Biggest five-year swings in Total Debt: surged 1674.0% in 2021 and later tumbled 94.7% in 2022.
  • Year by year, Total Debt stood at $110000.0 in 2021, then dropped by 9.09% to $100000.0 in 2022, then soared by 65.0% to $165000.0 in 2024, then plummeted by 63.64% to $60000.0 in 2025.
  • Business Quant data shows Total Debt for GTHP at $60000.0 in Q4 2025, $108000.0 in Q3 2025, and $95000.0 in Q2 2025.